-

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May:

  • BofA Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 1:40 pm (PDT) and
  • RBC 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 10:30 am (EDT)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram.

Contacts

Incyte Contacts
Media
media@incyte.com

Investors
ir@incyte.com

Industry:

Incyte

NASDAQ:INCY
Release Summary
Incyte to Present at Upcoming Investor Conferences
Release Versions
English

Contacts

Incyte Contacts
Media
media@incyte.com

Investors
ir@incyte.com

More News From Incyte

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates...

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Data to Be Highlighted in Four Rapid Oral Presentations at ESMO 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers...

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

WILMINGTON, Del.--(BUSINESS WIRE)--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types...
Back to Newsroom